“The phlebotomists haven’t taken 100 days of strike action on a whim. They don’t want special treatment. They just want to be ...

BROCKWAY — Brockway Center for Arts & Technology graduated 10 students from its 12th certified clinical medical assistant and phlebotomy class on June 17.

Removing 10 per cent of a patient’s blood before major liver surgery and giving it back afterwards reduced transfusions by ...

Sponsored Content: Blake Learns to Draw Blood with Midwest Technical Institute’s Phlebotomy Program Blake gets a lesson in phlebotomy at MTI. Phlebotomists work in a variety of medical facili… ...

Shara Slinkard, a Southeast Missouri native with 24 years of experience, has joined EBO Labs as lead phlebotomist, overseeing lab operations and patient care in Cape Girardeau.

Key Takeaways Rusfertide reduces or eliminates phlebotomy needs in polycythemia vera, improving quality of life and symptom control. The VERIFY trial showed 77% clinical response with rusfertide, ...

Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...

Rusfertide significantly reduced phlebotomy needs in PV patients, with 76.9% achieving clinical response versus 32.9% in the placebo group. The therapy maintained hematocrit levels below 45% in 62 ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%.

Rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic, is under evaluation in the Phase 3 VERIFY study for its potential to regulate iron homeostasis and red blood cell ...